Does Time-to-Chemotherapy after Primary Complete Macroscopic Cytoreductive Surgery Influence Prognosis for Patients with Epithelial Ovarian Cancer? A Study of the FRANCOGYN Group

Affiliation auteurs!!!! Error affiliation !!!!
TitreDoes Time-to-Chemotherapy after Primary Complete Macroscopic Cytoreductive Surgery Influence Prognosis for Patients with Epithelial Ovarian Cancer? A Study of the FRANCOGYN Group
Type de publicationJournal Article
Year of Publication2021
AuteursRocher G, Gaillard T, Uzan C, Collinet P, Bolze P-A, Ballester M, Bendifallah S, Ouldamer L, Touboul C, Huchon C, Lavoue V, Dabi Y, Akladios C, Coutant C, Raimond E, Bricou A, Canlorbe G, Azais H
JournalJOURNAL OF CLINICAL MEDICINE
Volume10
Pagination1058
Date PublishedMAR
Type of ArticleArticle
Mots-clésChemotherapy, Epithelial ovarian cancer, prognosis
Résumé

{To determine if the time-to-chemotherapy (TTC) after primary macroscopic complete cytoreductive surgery (CRS) influences recurrence-free survival (RFS) and overall survival (OS) in patients with epithelial ovarian cancer (EOC). We conducted an observational multicenter retrospective cohort analysis of women with EOC treated from September 2006 to November 2016 in nine institutions in France (FRANCOGYN research group) with maintained EOC databases. We included women with EOC (all FIGO stages) who underwent primary complete macroscopic CRS prior to platinum-based adjuvant chemotherapy. Two hundred thirty-three patients were included: 73 (31.3%) in the early-stage group (ESG) (FIGO I-II), and 160 (68.7%) in the advanced-stage group (ASG) (FIGO III-IV). Median TTC was 43 days (36-56). The median OS was 77.2 months (65.9-106.6). OS was lower in the ASG when TTC exceeded 8 weeks (70.5 vs. 59.3 months
DOI10.3390/jcm10051058